Revenue growth confirms Attruby's commercial trajectory, but the EPS miss may pressure the stock near-term. Key catalysts are the BBP-418 PDUFA in November 2026, encaleret PDUFA in May 2027, and upcoming data at ESC 2026. Monitor Attruby market share gains and the impact of the $1B financing on launch execution.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $84.67entry
- T+1 · 3mo ago −0.98%α −1.23% · $83.84
- T+5 · 3mo ago −2.00%α −1.59% · $82.98
- T+20 · 2mo ago −10.15%α −9.09% · $76.08
- T+60 · 13d ago −9.19%α −9.06% · $76.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio reported Q2 2026 total revenues of $243.7M (+120.5% YoY), driven by $222.4M in Attruby net product revenue (+211% YoY), but GAAP EPS of $(0.78) missed consensus of $(0.64) by 22%. The company is investing heavily in three upcoming launches and closed a $1B preferred equity financing post-quarter, strengthening its balance sheet for pipeline expansion.
Key Financial Metrics
Key Facts
- Q2 2026 total revenues $243.7M, up 120.5% YoY from $110.6M
- Attruby net product revenue $222.4M, up 211% YoY from $71.5M
- GAAP net loss per share $(0.78) vs consensus $(0.64), 21.9% miss
- Three NDAs under FDA Priority Review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 8, 2027), infigratinib (submitted)
- $1B preferred equity financing closed July 1, 2026, led by Sixth Street
- Cash, equivalents, and marketable securities $720.2M as of June 30, 2026
- Operating expenses surged to $350.8M (+43.3% YoY) as company scales for three launches
Financial Impact
Revenue growth offset by 22% EPS miss and 43% operating expense increase; net loss improved to $152.2M from $181.9M YoY
Risk Factors
- EPS miss of 22% vs consensus raises concerns about expense trajectory
- R&D and SG&A spending growing faster than revenue, delaying profitability
- Dependence on Attruby for near-term revenue; pipeline approvals are binary events
- High debt load with $2.5B in notes and deferred royalty obligations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342182 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers